Manas AI

AI-driven drug discovery company.

AIDrug discoveryOncologyBiotech

Active^{Source [1]}Last verified Oct 2, 2026

About Manas AI

Manas AI is an AI-native biopharmaceutical company that uses neuro-symbolic AI models in a pipeline running from target identification toward clinical trials, covering small molecules, antibodies and siRNA therapies.^{Source [5]}^{Source [3]}

It launched in January 2025 with an initial focus on triple-negative breast cancer, prostate cancer and lymphoma, and said it planned to expand later to autoimmune and rare diseases. It uses Microsoft Azure for large-scale compute.^{Source [1]}^{Source [2]}

The company is led by co-founder and CEO Siddhartha Mukherjee. It has raised $50.6 million in seed funding and in January 2026 announced a deep integration with Schrödinger's physics-based discovery platform.^{Source [3]}^{Source [4]}

What happened

Launched on January 27, 2025, co-founded by oncologist Siddhartha Mukherjee and Reid Hoffman, with $24.6 million in seed funding. It focuses on discovering cancer medicines using AI and Microsoft Azure.^{Source [1]}^{Source [2]}^{Source [6]}

Timeline

2026-01-12Announced a deep integration with Schrödinger's physics plus AI discovery platform.^{Source [4]}
2025-09-23Announced a $26 million seed extension and named Ujjwal Singh co-founder and CTO.^{Source [3]}
2025-04-15Appointed Jonathan Baell as chief scientific officer.^{Source [7]}
2025-01-27Launched with $24.6 million in seed funding.^{Source [1]}^{Source [2]}

Products and brands

AI drug discovery platform: Neuro-symbolic, science-based foundation models and an end-to-end discovery pipeline for new medicines.^{Source [5]}^{Source [3]}
Project Cosmos: Initiative to map fundamental rules of drug binding.^{Source [1]}

How it makes money: Discovers and develops its own drug candidates, starting with cancer, using AI models, cloud compute and wet-lab testing.^{Source [1]}^{Source [2]}

Leadership

Siddhartha Mukherjee	CEO and Co-founder^{Source [3]}^{Source [4]}
Ujjwal Singh	Co-founder and Chief Technology Officer^{Source [3]}^{Source [5]}	Since 2025
Jonathan Baell	Chief Scientific Officer^{Source [7]}^{Source [5]}	Since 2025

Funding and financials

Date	Round	Amount	Investors
2025-09	Seed extension^{Source [3]}	$26 million	General Catalyst, The General Partnership, Wisdom Ventures, Blitzscaling Ventures, Westbound Equity Partners, Mosaic Ventures and others
2025-01	Seed^{Source [1]}^{Source [2]}	$24.6 million	Led by General Catalyst and Reid Hoffman, with Greylock

People on Founded, and where they went next

1 person on record, connected to 7 other companies.

Person	Here	Also built
Reid Hoffman	Co-founder2025	Inflection AI2022ActiveMicrosoft2017 to nowIPOGreylock2009 to nowActiveLinkedIn2002 to 2016AcquiredPayPal2000 to 2002IPOConfinity1998 to 2000MergedSocialNet.com1997 to 2000Status unknown

Sources

Manas AI Launches to Transform Discovery of Novel Cancer Medicines, Manas AI, 2025-01-27. Accessed Oct 2, 2026.
Reid Hoffman's Manas AI raises $24.6M, a fraction of other AI drug discovery startups, TechCrunch, 2025-01-27. Accessed Oct 2, 2026.
Manas AI Announces $26M Seed Extension and the Appointment of Ujjwal Singh as Co-Founder and Chief Technology Officer, Manas AI, 2025-09-23. Accessed Oct 2, 2026.
Manas AI Secures Strategic Advantage through Unique Deep Integration with Schrödinger's Physics + AI Discovery Platform, Manas AI, 2026-01-12. Accessed Oct 2, 2026.
Manas AI, Manas AI. Accessed Oct 2, 2026.
Reid Hoffman launches Manas AI, a new drug discovery startup, CNBC, 2025-02-02. Accessed Sep 28, 2026.
Manas AI Appoints Jonathan Baell, PhD, as Chief Scientific Officer, Manas AI, 2025-04-15. Accessed Oct 2, 2026.

Suggest a correction / Editorial policy